Marshall Wace LLP Sells 282,142 Shares of Autolus Therapeutics plc (NASDAQ:AUTL)

Marshall Wace LLP lessened its holdings in shares of Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 27.1% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 757,535 shares of the company's stock after selling 282,142 shares during the period. Marshall Wace LLP owned approximately 0.28% of Autolus Therapeutics worth $2,636,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in AUTL. ProShare Advisors LLC acquired a new stake in Autolus Therapeutics in the 2nd quarter worth $43,000. Bayesian Capital Management LP acquired a new stake in shares of Autolus Therapeutics during the 1st quarter valued at about $100,000. Daiwa Securities Group Inc. increased its stake in Autolus Therapeutics by 2,659.7% in the second quarter. Daiwa Securities Group Inc. now owns 15,868 shares of the company's stock valued at $55,000 after acquiring an additional 15,293 shares during the period. B. Riley Wealth Advisors Inc. acquired a new position in Autolus Therapeutics in the first quarter worth about $108,000. Finally, SG Americas Securities LLC bought a new position in Autolus Therapeutics during the first quarter worth about $127,000. Institutional investors own 72.83% of the company's stock.

Autolus Therapeutics Price Performance

NASDAQ:AUTL traded up $0.06 during mid-day trading on Friday, reaching $3.96. 257,127 shares of the company were exchanged, compared to its average volume of 1,371,765. The company has a quick ratio of 18.55, a current ratio of 18.55 and a debt-to-equity ratio of 0.09. The stock has a market cap of $1.05 billion, a PE ratio of -3.25 and a beta of 2.05. Autolus Therapeutics plc has a 12 month low of $2.13 and a 12 month high of $7.45. The company has a fifty day moving average of $3.95 and a 200 day moving average of $4.28.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.03). On average, research analysts anticipate that Autolus Therapeutics plc will post -0.84 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Needham & Company LLC reiterated a "buy" rating and issued a $9.00 price objective on shares of Autolus Therapeutics in a research note on Monday, June 17th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $8.70.

Autolus Therapeutics Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.